|Bid||16.30 x 2900|
|Ask||17.05 x 3100|
|Day's Range||16.98 - 18.89|
|52 Week Range||3.92 - 20.09|
|Beta (5Y Monthly)||2.56|
|PE Ratio (TTM)||N/A|
|Earnings Date||Feb 25, 2020 - Mar 01, 2020|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||25.29|
The European Commission bestows an orphan drug status on BioLineRx's (BLRX) lead candidate Motixafortide, currently being evaluated with Merck's Keytruda to treat pancreatic cancer. Stock up.
Aclaris (ACRS) announces favorable preliminary data from the phase I study on its investigational candidate ATI-450, presently being developed for treating immuno-inflammatory diseases. Stock rises.
Karyopharm Therapeutics Inc. (KPTI), an oncology-focused pharmaceutical company, today announced preliminary unaudited fourth quarter and full year 2019 net product sales for XPOVIO® (selinexor), the Company’s first-in-class, oral Selective Inhibitor of Nuclear Export (SINE) compound, and provided additional updates on the product’s commercial launch. Based on preliminary unaudited financial information, Karyopharm expects net product sales of XPOVIO to be between $17 and $18 million during the fourth quarter and between $30 and $31 million for the full year 2019. In less than 6 months on the market, XPOVIO has been prescribed by more than 550 unique physicians and healthcare accounts.
Zacks.com featured highlights include: Cassava Sciences, Rubicon Project, Talos Energy, Teekay Tankers and Karyopharm Therapeutics
Investors target stocks that are witnessing a bullish run. Actually, stocks seeing price strength have a high chance of carrying the momentum forward.
NEWTON, Mass., Jan. 07, 2020 -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), an oncology-focused pharmaceutical company, today announced that Michael Kauffman, MD, PhD, Chief.
Karyopharm Therapeutics Inc. (KPTI), an oncology-focused pharmaceutical company, today announced that the Compensation Committee of Karyopharm’s Board of Directors granted stock options to purchase an aggregate of 25,000 shares of Karyopharm’s common stock to seven newly-hired employees, with a grant date of December 31, 2019. The stock options were granted as inducements material to the new employees entering into employment with Karyopharm in accordance with NASDAQ Listing Rule 5635(c)(4). Each of the stock options has an exercise price of $19.17 per share, the closing price of Karyopharm’s common stock of December 31, 2019.
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Dec. 23) 10X Genomics Inc (NASDAQ: TXG )(reacted to a ruling ...
Karyopharm Therapeutics Inc. (KPTI), an oncology-focused pharmaceutical company, today announced it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) seeking accelerated approval for XPOVIO® (selinexor), the Company’s first-in-class, oral Selective Inhibitor of Nuclear Export (SINE) compound, as a new treatment for patients with relapsed or refractory diffuse large B-Cell lymphoma (DLBCL) after at least two prior multi-agent therapies and who are ineligible for stem cell transplantation, including CAR-T (chimeric antigen receptor modified T cell) therapy. XPOVIO has received both Orphan Drug and Fast Track designations from the FDA for this indication.
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...
Massachusetts life science companies were involved in $34 billion worth of mergers and acquisitions this year. Experts say next year will be even busier.
We are still in an overall bull market and many stocks that smart money investors were piling into surged through the end of November. Among them, Facebook and Microsoft ranked among the top 3 picks and these stocks gained 54% and 51% respectively. Hedge funds' top 3 stock picks returned 41.7% this year and beat […]
Investors have been piling into exchange traded funds again this year, mostly pure beta, core equity and fixed income funds. The list of the top asset-gathering ETFs reads like rundown of the usual suspects. There's nothing wrong with that, but as investors flock to broad market equity and aggregate bond funds to keep up with the Joneses, they miss out on tactical opportunities like the Virtus LifeSci Biotech Clinical Trials ETF (NYSE: BBC).
-- Once-Weekly Oral Selinexor in Combination with Weekly Kyprolis® and Low Dose Dexamethasone Demonstrates 71% Overall Response Rate, Including a Complete Response Rate of 21%,.
Karyopharm Therapeutics Inc. (KPTI), an oncology-focused pharmaceutical company, today announced that two presentations highlighting new and updated data relating to XPOVIO® (selinexor), the Company’s first-in-class, oral Selective Inhibitor of Nuclear Export (SINE) compound, will be given at the American Society of Hematology (ASH) 2019 Annual Meeting taking place December 7-10, 2019 in Orlando. The first study, which will be featured in an oral presentation, describes updated data from the Phase 1b/2 STOMP study evaluating the all oral regimen of selinexor in combination with Pomalyst® (pomalidomide) and low-dose dexamethasone (dex) (SPd) in patients with relapsed or refractory multiple myeloma.
Does Karyopharm Therapeutics (KPTI) have what it takes to be a top stock pick for momentum investors? Let's find out.
-- Updated Results from the Pomalyst® and Kyprolis® Arms of the Phase 1b/2 STOMP Study Evaluating Selinexor in Combination with Other Approved Myeloma Therapies in Relapsed or.
Karyopharm Therapeutics and Pieris Pharmaceuticals are climbing this week on positive news, while Supernus Pharmaceuticals takes a hit.
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Nov. 4) Agile Therapeutics Inc (NASDAQ: AGRX )(follow-on rally ...